The helicobacter pylori (H. pylori) non-invasive testing market in Middle East & Africa is expected to grow from US$ 39.86 million in 2022 to US$ 54.80 million by 2028. It is estimated to grow at a CAGR of 5.4% from 2022 to 2028.
The limited success rate of the treatment of H. pylori infection is mainly due to resistance to clarithromycin and metronidazole. Therefore, research will be focused on the identification of bacterial resistance. Smart Gene was developed based on the concept of point of care genetic testing. A recent study has shown that H. pylori DNA can be detected in human stool specimens with PCR tests using stool specimens. The novel PCR test can sensitively detect H. pylori DNA in stool, along with mutations causing clarithromycin resistance. There is a significant correlation between the presence of such mutations and the outcome of clarithromycin-based eradication treatment. The consequences of this study suggest that stool can be used to determine resistance with a high correlation to eradication status. This stool/PCR test can potentially reduce healthcare costs with an updated algorithm.
The survey conducted by Gulf news in 2019 revealed that 88% of UAE citizens do not visit clinics or hospitals for preventive screening for cancer. A few factors limiting the early screening of cancer include the cost of screening, cultural sensitivities, and psychological denial about the disease. The prevalence of cancer and high healthcare expenditure are expected to boost the growth of the Helicobacter pylori (H. pylori) non-invasive testing market in the UAE during the forecast period.
The limited success rate of the treatment of H. pylori infection is mainly due to resistance to clarithromycin and metronidazole. Therefore, research will be focused on the identification of bacterial resistance. Smart Gene was developed based on the concept of point of care genetic testing. A recent study has shown that H. pylori DNA can be detected in human stool specimens with PCR tests using stool specimens. The novel PCR test can sensitively detect H. pylori DNA in stool, along with mutations causing clarithromycin resistance. There is a significant correlation between the presence of such mutations and the outcome of clarithromycin-based eradication treatment. The consequences of this study suggest that stool can be used to determine resistance with a high correlation to eradication status. This stool/PCR test can potentially reduce healthcare costs with an updated algorithm.
Market Overview
The UAE has witnessed significant growth in the Helicobacter pylori (H. pylori) non-invasive testing market over the past few years. The market growth in the UAE is attributed to the increase in healthcare expenditure and the high prevalence of stomach cancer. According to the NIH report, stomach cancer is the most common type of cancer in the country. Additionally, stomach cancer is a significant contributor to the global burden of stomach cancer morbidity and mortality.The survey conducted by Gulf news in 2019 revealed that 88% of UAE citizens do not visit clinics or hospitals for preventive screening for cancer. A few factors limiting the early screening of cancer include the cost of screening, cultural sensitivities, and psychological denial about the disease. The prevalence of cancer and high healthcare expenditure are expected to boost the growth of the Helicobacter pylori (H. pylori) non-invasive testing market in the UAE during the forecast period.
Middle East & Africa Helicobacter Pylori (H. pylori) Non-invasive Testing Market Segmentation
The Middle east & Africa helicobacter pylori (H. pylori) non-invasive testing market is segmented on test type, test method, end user, and country. -Based on test type, the Middle east & Africa Helicobacter pylori (H. pylori) non-invasive testing market is segmented into serology, stool antigen, and urea breathe. In 2022, the urea breath segment is expected to hold the largest share of the market.- Based on test method, the Middle east & Africa Helicobacter pylori (H. pylori) non-invasive testing market is bifurcated into laboratory based and point of care. The laboratory based segment is expected to hold a larger share of the market in 2022.
- Based on end user, the Middle east & Africa Helicobacter pylori (H. pylori) non-invasive testing market is segmented into hospitals, clinics, and diagnostic laboratories. The diagnostic laboratories segment is expected to hold the largest share of the market in 2022.
- Based on country, the Middle East & Africa Helicobacter pylori (H. pylori) non-invasive testing market is segmented into Saudi Arabia, South Africa, the UAE, and the Rest of Middle East & Africa. Further, UAE dominated the market in 2022. Abbott Laboratories; Bio-Rad Laboratories Inc.; CerTest Biotec; Coris BioConcept; DiaSorin S.p.A.; Meridian Bioscience Inc.; QuidelOrtho Corporation; Sekisui Diagnostics; Shenzhen Zhonghe Headway Bio-Sci & Tech Co., Ltd; and Thermo Fisher Scientific Inc. are the leading companies operating in the helicobacter pylori (H. pylori) non-invasive testing market in the Middle East & Africa.
Table of Contents
1. Introduction
3. Research Methodology
4. MEA Helicobacter Pylori (H. pylori ) Non-invasive Testing Market - Market Landscape
5. MEA Helicobacter Pylori (H. pylori ) Non-Invasive Testing Market - Key Industry Dynamics
6. Helicobacter pylori (H. pylori ) Non-Invasive Testing Market- Global Analysis
7. MEA Helicobacter pylori (H. pylori ) Non-Invasive Testing Market Analysis- by Test Type
8. MEA Helicobacter pylori (H. pylori ) Non-Invasive Testing Market Analysis- by Test Method
9. MEA Helicobacter pylori (H. pylori ) Non-invasive Testing Market Analysis- by End User
10. MEA Helicobacter Pylori (H. pylori ) Non-invasive Testing Market Revenue and Forecasts to 2028 - Country Analysis
11. Helicobacter Pylori (H. Pylori ) Non-Invasive Testing Market-Industry Landscape
12. Company Profile
13. Appendix
List of Tables
List of Figures
Companies Mentioned
- Abbott Laboratories
- Bio-Rad Laboratories Inc.
- Certest Biotec; Coris Bioconcept
- Coris Bioconcept
- Diasorin S.P.A.
- Meridian Bioscience Inc.
- Quidelortho Corporation
- Sekisui Diagnostics
- Shenzhen Zhonghe Headway Bio-Sci & Tech Co., Ltd
- Thermo Fisher Scientific Inc.
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 119 |
| Published | November 2022 |
| Forecast Period | 2022 - 2028 |
| Estimated Market Value ( $ | $ 39.86 Million |
| Forecasted Market Value ( $ | $ 54.8 Million |
| Compound Annual Growth Rate | 5.4% |
| Regions Covered | Africa, Middle East |
| No. of Companies Mentioned | 10 |
